The GST Council's next-generation reform package, effective September 22, 2025, introduced sweeping rate rationalisations. The revised structure shifts to a simplified two-slab system (5% and 18%), reducing tax burdens on essentials. Key pharmaceutical benefits include 33 life-saving drugs and diagnostic kits moved from 12% to 0%, Ayurveda/Unani/Homoeopathy medicines reduced from 12% to 5%, and job work in pharma manufacturing cut from 12% to 5%. Household costs are projected to fall by up to 13%, with the reform expected to add 0.1 percentage point to GDP growth.